surpass trial tirzepatide Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the Clinical Program | Cardiovascular Diabetology Read now: The SURPASS-EARLY trial

Clinical trials have shown that individuals taking Semaglutide experienced substantial weight reduction, making it a valuable tool for those struggling with obesity

The odor, once suspected of being a product of a defective metabolism, is actually harmless

Sodium-glucose cotransporter-2 inhibitors improve fibroscan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes

Diagnostic and Statistical Manual of Mental Disorders DSM-5 5th (2013)

If side effects are affecting daily function, ask your prescriber what options are appropriate for your situation

Some people find semaglutide easier on the stomach than tirzepatide